Mild COVID-19 induces lasting antibody protection: US Study - The findings, published May 24 in the journal Nature, suggest that mild cases of COVID-19 leave those infected with lasting antibody protection.
Researchers at Washington University School of Medicine in St. Louis and Stanford University School of Medicine have found that normal exposure to light can drive the formation and growth of optic nerve tumors in mice and maybe people with a genetic predisposition. Such tumors can lead to vision loss.
Read Time:
Throughout the pandemic, doctors have seen evidence that men with COVID-19 fare worse, on average, than women with the infection. One theory is that hormonal differences between men and women may make men more susceptible to severe disease. And since men have much more testosterone than women, some scientists have speculated that high levels of testosterone may be to blame.
But a new study from Washington University School of Medicine in St. Louis suggests that, among men, the opposite may be true: that low testosterone levels in the blood are linked to more severe disease. The study could not prove that low testosterone is a cause of severe COVID-19; low levels could simply serve as a marker of some other causal factors. Still, the researchers urge caution with ongoing clinical trials investigating hormonal therapies that block or lower testosterone or increase estrogen as a treatment for men with COVID-19.
Long after recovering from mild cases of COVID, people still have immune cells in their body releasing antibodies against the virus, according to a study from WashU.